LUCODACIGENE PARVEC
UNII MP86U34PJY

Substance Identification & Data

This profile provides standardized clinical and technical data for Lucodacigene Parvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) MP86U34PJY.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3062982-56-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

MP86U34PJY

CAS Registry Number

3062982-56-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LUCODACIGENE PARVEC

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13894

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lucodacigene Parvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

LUCODACIGENE PARVEC

LUCODACIGENE PARVEC [INN]

RECOMBINANT, SELF-COMPLEMENTARY NON-REPLICATING ADENO-ASSOCIATED VIRUS SEROTYPE 9 (RAAV9) VECTOR ENCODING CODON-OPTIMISED HUMAN ASPARTOACYLASE (ASPA, ASP, AMINOACYLASE-2, ACY2). THE TRANSGENE IS PRECEDED BY A KOZAK SEQUENCE, WITH EXPRESSION UNDER CONTROL OF A HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA ACTIN PROMOTER (CB6) AND TERMINATED BY A RABBIT .BETA.-GLOBIN GENE POLYADENYLATION SIGNAL; FLANKED BY ADENO-ASSOCIATED VIRUS 2 (AAV2) INVERTED TERMINAL REPEATS (ITRS) (LUCODACIGENE PARVEC)

External Clinical & Regulatory Resources

Previous UNIIMP84D73N0X

Next UNIIMP8C8AZ4ZF